CND Life Sciences key facts
as of Oct 2026- Developer of a medical diagnostic platform designed to detect key pathological markers in the peripheral nervous system.
- CND Life Sciences is valued at approximately $30.5M as of Oct 2026 (last reported valuation).
- It has raised $29.3M across 7 recorded rounds; the latest was Debt ($4.3M) in Jun 2026.
- Notable investors include Labcorp Venture Fund, MBX Capital, Cambrian Capital, Blue Stone Venture, BlueStone Venture Partners — 14 tracked in total.
- CND Life Sciences has filed 10 Form Ds with the SEC since 2021, most recently May 2025 ($8.6M sold to 38 investors).
- Status: Privately Held (backing).
CND Life Sciences's last reported valuation, Mar 2023. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch CND Life Sciences: the Monday email on marks, rounds and moves
CND Life Sciences funding rounds
7 roundsWho backs CND Life Sciences
14+Membership and data by Private Market View
CND Life Sciences valuation
CND Life Sciences's last reported valuation was $30.5 million in Mar 2023. No priced round, secondary trade or fund mark has surfaced since.
How much has CND Life Sciences raised?
CND Life Sciences has raised $29.3 million across 7 recorded rounds since 2021. The largest was an $8.6 million early-stage round in Feb 2025; the most recent was a $4.3 million debt round in Jun 2026.
CND Life Sciences has filed 10 Form Ds with the SEC since 2021, most recently in May 2025 ($8.6 million sold to 38 investors).
CND Life Sciences investors
14 investors are on record for CND Life Sciences, including Labcorp Venture Fund, MBX Capital, Cambrian Capital and Blue Stone Venture. The debt round in Jun 2026 drew 1 investor.
About CND Life Sciences
Developer of a medical diagnostic platform designed to detect key pathological markers in the peripheral nervous system. The company's platform detects, visualizes, and quantifies the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers and confirms synucleinopathy in patients with suspected Parkinson's disease, enabling medical experts with a convenient, accurate, minimally invasive alternative to aid in the diagnosis of neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- Scottsdale, AZ, United States
- Founded
- 2017
- Employees
- 136
- Website
- cndlifesciences.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.